Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Foretinib + Veliparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Foretinib||GSK1363089G|XL880|EXEL-2880||MET Inhibitor 57 ROS1 Inhibitor 20 TrkA Receptor Inhibitor 8 TYRO3 Inhibitor 8 VEGFR2 Inhibitor 36||Foretinib (GSK1363089) is a multi-kinase inhibitor with activity against several receptor tyrosine kinases, including MET, KDR (VEGFR2), as well as ROS1 and NTRK fusions, which may result in decreased tumor angiogenesis and growth (PMID: 19808973, PMID: 26372962, PMID: 29463555, PMID: 30501104).|
|Veliparib||ABT-888||PARP Inhibitor (Pan) 28||Veliparib (ABT-888) is a PARP1 and PARP2 inhibitor, which inhibits DNA repair and induces lethality in homologous recombination deficient cells, and may enhance the sensitivity of chemotherapeutic agents (PMID: 26251615, PMID: 31074636, PMID: 32452601).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|